Carcinoid Clinical Trials
CPMC Cancer Services
Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page
Further protocol information can be found on the links below at ClinicalTrials.gov
Active Trials
Title: Phase III Trial Prospective Randomized Comparison of Depot Octerotide Plus Interferon Alpha Versus Deopot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Description: Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Investigators: CPMC Oncologists
Eligibility: Subjects with unresectable metastatic or locally advanced, low- or intermediate-grade neuroendocrine carcinoma
Status: Active and open to enrollment
Contact: Brenda Eng, 415-600-1775,
Email: EngB@cpmcri.org about Study SWOG S0518
- updated May 2011
Back to top